35 results about "Neoplasm DNA" patented technology

The invention relates to molecular biology detection of genes in the technical field of biology, and particularly relates to a method for detecting c-MET gene amplification by utilizing a digital PCR(Polymerase Chain Reaction) technology. The detection method comprises the following steps: firstly, designing and synthesizing upstream and downstream primers for detecting c-MET gene amplification and the probe for detecting the c-MET gene amplification for c-MET genes; then designing digital PCR detection parameters; judging whether a sample to be detected contains c-MET gene amplification through the digital PCR technology. The primer and the probe designed by the invention have strong specificity, are applied to non-tumorous tissues through the digital PCR detection, the accuracy is high,and the sensitivity can be up to 0.01 percent. The length of an amplification fragment of the primer designed and synthesized by the method disclosed by the invention is less than 100bp, so that thefragment is particularly suitable for amplifying small-fragment DNA samples such as plasma free DNA, and variation of c-MET amplification with extremely low abundance ratio can be detected from cfDNA,tumor DNA is detected from blood circulation of patients in the early stage of tumors; moreover, the technical problem of risk of invasive sampling detection is overcome, and the primer, the probe and the detection method have extremely important effects on guidance of clinical treatment and improvement of prognosis of patients.

It is disclosed herein that (a) an anti-tumor DNA vaccine delivered using a MIP DNA vector is a less effective tumor treatment than the corresponding anti-tumor DNA vaccine delivered using a conventional pDNA vector, despite the MIP DNA vector eliciting a higher frequency of antigen-specific CD8+ T cells; and (b) tumor infiltrating CD8+ T cells in animals immunized with the MIP DNA vector express higher levels of the immune checkpoint protein LAG-3 than animals immunized with a conventional pDNA vector, while the expression levels of other immune checkpoint proteins was the same for both groups. Based on these findings, improved methods and compositions for administering DNA vaccines are disclosed. Specifically, DNA vaccines delivered with MIP DNA are administered along with a LAG-3 pathway blocking agent, resulting in a more effective vaccine-induced cellular immune response.